Scholars@Duke

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.

Publication ,  Journal Article
Capodanno, D; Baber, U; Bhatt, DL; Collet, J-P; Dangas, G; Franchi, F; Gibson, CM; Gwon, H-C; Kastrati, A; Kimura, T; Lemos, PA; Lopes, RD ...
Published in: Nat Rev Cardiol
December 2022
Published version (DOI) Link to item

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this paradigm by testing the efficacy and safety of P2Y12 inhibitor monotherapy (that is, without aspirin) following a short course of DAPT. Collectively, these studies suggested a reduction in the risk of major bleeding and no significant increase in thrombotic or ischaemic events compared with guideline-recommended DAPT. Current recommendations are evolving to inform clinical practice on the ideal candidates for P2Y12 inhibitor monotherapy after PCI. Generalizing the results of studies of P2Y12 inhibitor monotherapy requires a thorough understanding of their design, populations, interventions, comparators and results. In this Review, we provide an up-to-date overview on the use of P2Y12 inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions.

Duke Scholars

Renato Delascio Lopes
Author Renato Delascio Lopes Medicine, Cardiology
Sunil Vadlakonda Rao
Author Sunil Vadlakonda Rao Medicine, Cardiology

Published In

Nat Rev Cardiol

DOI

10.1038/s41569-022-00725-6

EISSN

1759-5010

Publication Date

December 2022

Volume

19

Issue

12

Start / End Page

829 / 844

Location

England

Related Subject Headings

  • Treatment Outcome
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Dual Anti-Platelet Therapy
  • Drug Therapy, Combination
  • Cardiovascular System & Hematology
  • Aspirin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Capodanno, D., Baber, U., Bhatt, D. L., Collet, J.-P., Dangas, G., Franchi, F., … Angiolillo, D. J. (2022). P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol, 19(12), 829–844. https://doi.org/10.1038/s41569-022-00725-6
Capodanno, Davide, Usman Baber, Deepak L. Bhatt, Jean-Philippe Collet, George Dangas, Francesco Franchi, C Michael Gibson, et al. “P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.” Nat Rev Cardiol 19, no. 12 (December 2022): 829–44. https://doi.org/10.1038/s41569-022-00725-6.
Capodanno D, Baber U, Bhatt DL, Collet J-P, Dangas G, Franchi F, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol. 2022 Dec;19(12):829–44.
Capodanno, Davide, et al. “P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.” Nat Rev Cardiol, vol. 19, no. 12, Dec. 2022, pp. 829–44. Pubmed, doi:10.1038/s41569-022-00725-6.
Capodanno D, Baber U, Bhatt DL, Collet J-P, Dangas G, Franchi F, Gibson CM, Gwon H-C, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O’Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol. 2022 Dec;19(12):829–844.

Published In

Nat Rev Cardiol

DOI

10.1038/s41569-022-00725-6

EISSN

1759-5010

Publication Date

December 2022

Volume

19

Issue

12

Start / End Page

829 / 844

Location

England

Related Subject Headings

  • Treatment Outcome
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Dual Anti-Platelet Therapy
  • Drug Therapy, Combination
  • Cardiovascular System & Hematology
  • Aspirin